Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Core Viewpoint - Eli Lilly and Company plans to invest in four new pharmaceutical manufacturing sites in the U.S., representing the largest pharmaceutical manufacturing investment in U.S. history, with total capital commitments exceeding $50 billion since 2020 [1][3]. Group 1: Investment and Job Creation - The new sites will create over 3,000 high-wage jobs for skilled workers, including engineers and scientists, and nearly 10,000 construction jobs during development [3][4]. - The investment is driven by optimism in the company's pipeline across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience [3]. Group 2: Manufacturing Focus - Three of the new sites will focus on manufacturing active pharmaceutical ingredients (API) to strengthen the supply chain, while the fourth will enhance the global parenteral manufacturing network for injectable therapies [2]. - The company aims to build state-of-the-art manufacturing infrastructure to support next-generation modalities like small molecules and biologics [4]. Group 3: Economic Impact - Expected benefits for local communities include increased local spending, tax revenue, economic diversification, improved infrastructure, and training opportunities [4]. - The Tax Cuts and Jobs Act of 2017 has been pivotal in facilitating these domestic manufacturing investments, with the company emphasizing the need for policy extensions [5]. Group 4: Future Plans - Eli Lilly is currently negotiating with several states for the new sites and plans to announce their locations in 2025, with production expected to start within five years [6][7].